Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants.
Recently, Yb-169 has been considered as a potential replacement for I-125 and Pd-103 in permanent implants. In spite of the uncertainties in the parameters necessary for an accurate radiobiological modelling, the linear quadratic model can be useful in the comparative evaluation of the radiotherapeutic merit of similar implants. In order to find out if a Yb-169 permanent implant can be made biologically 'equivalent' to an I-125 implant, we studied the dependence of local control on the tumour cell radiosensitivity and on the balance between the rate of tumour cell killing and tumour cell proliferation, for rapidly and slowly proliferating tumours. The extrapolated response dose (ERD) has been calculated for tumour and late reacting normal tissue for both types of implants and the possible biological restrictions due to the normal tissue tolerance have been discussed. Our theoretical analysis is consistent with the clinical results published for I-125 permanent implants in prostate tumours and meningiomas. It predicts that Yb-169, which has only recently been used in human tumours, can provide comparable tumour control for permanent implants in slowly proliferating tumours with an initial dose rate of 13 cGy h-1. Control might be extended to rapidly proliferating tumours by increasing the initial dose rate within a range consistent with an acceptable level of normal tissue late reaction.
Lazarescu
G R
GR
Windsor Regional Cancer Center, Ontario Cancer Treatment and Research Foundation, Windsor, Canada.
Battista
J J
JJ
D055592:Biophysical Phenomena; D001703:Biophysics; D001918:Brachytherapy / Q000379:methods*; D016923:Cell Death / Q000528:radiation effects; D002455:Cell Division / Q000528:radiation effects; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D009369:Neoplasms / Q000473:pathology / Q000532:radiotherapy; D011853:Radiobiology; D011868:Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D012062:Relative Biological Effectiveness; D015018:Ytterbium / Q000008:administration & dosage* / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D011868:Radioisotopes; D015018:Ytterbium